Comparison of the performance of HPV tests in women with abnormal cytology: Results of a study within the NHS cervical screening programme

Cytopathology

Volumn 26, Issue 6, 2015, Pages 373-380

  Moss, S M ^a   Bailey, A ^b   Cubie, H ^c,h   Denton, K ^d,e   Sargent, A ^b   Muir, P ^e   Vipond, I B ^e   Winder, R ^f   Kitchener, H ^g  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b Public Health Laboratory   (United Kingdom)

^c Scottish Mycobacteria Reference Laboratory   (United Kingdom)

^d NORTH BRISTOL NHS TRUST   (United Kingdom)

^e PUBLIC HEALTH ENGLAND   (United Kingdom)

^f NATIONAL HEALTH SERVICE   (United Kingdom)

^g UNIVERSITY OF MANCHESTER   (United Kingdom)

^h UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Cervical cancer; Human papillomavirus assay; Papanicolaou test; Triage

Indexed keywords

VIRUS DNA; VIRUS RNA;

ADULT; COLPOSCOPY; COMPARATIVE STUDY; EARLY CANCER DIAGNOSIS; EMERGENCY HEALTH SERVICE; ENGLAND; EVALUATION STUDY; FEMALE; HUMAN; ISOLATION AND PURIFICATION; NUCLEIC ACID HYBRIDIZATION; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTION; PATHOLOGY; PROCEDURES; SENSITIVITY AND SPECIFICITY; SQUAMOUS INTRAEPITHELIAL LESION OF THE CERVIX; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX DYSPLASIA; UTERINE CERVIX TUMOR; VIROLOGY;

ADULT; ATYPICAL SQUAMOUS CELLS OF THE CERVIX; CERVICAL INTRAEPITHELIAL NEOPLASIA; COLPOSCOPY; DNA, VIRAL; EARLY DETECTION OF CANCER; ENGLAND; FEMALE; HUMANS; NUCLEIC ACID HYBRIDIZATION; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; RNA, VIRAL; SENSITIVITY AND SPECIFICITY; SQUAMOUS INTRAEPITHELIAL LESIONS OF THE CERVIX; TRIAGE; UTERINE CERVICAL NEOPLASMS;

EID: 84955689065     PISSN: 09565507     EISSN: 13652303     Source Type: Journal    
DOI: 10.1111/cyt.12210     Document Type: Article

References (19)

1. Moss S, Gray A, Legood R et al. Effect of testing for human papillomavirus as a triage during screening for cervical cancer: observational before and after study. Br Med J 2006;332:83-5.
2. Legood R, Gray A, Wolstenholme J, Moss S. Lifetime effects, costs, and cost effectiveness of testing for human papillomavirus to manage low grade cytological abnormalities: results of the NHS pilot studies. Br Med J 2006;332:79-85.
3. Cuschieri KS, Graham C, Moore C, Cubie HA. Human papillomavirus testing for the management of low-grade cervical abnormalities in the UK - influence of age and testing strategy. J Clin Virol 2007;38:14-8.
4. Kelly RS, Patnick J, Kitchener HC, Moss SM. HPV testing as a triage for borderline or mild dyskaryosis on cervical cytology: results from the Sentinel Sites study. Br J Cancer 2011;105:983-8.
5. Legood R, Sadique Z, Patnick J et al. Cost and logistics of alternative roll-out options for implementing human papillomavirus testing as a triage in cervical screening: results of the sentinel sites study. Br J Cancer 2012;107:1574-9.
6. Sharp L, Cotton S, Cruickshank M et al. The unintended consequences of cervical screening: distress in women undergoing cytologic surveillance. J Low Genit Tract Dis 2014;18:142-50.
7. Korfage IJ, Essink-Bot ML, Westenberg SM et al. How distressing is referral to colposcopy in cervical cancer screening? A prospective quality of life study. Gynecol Oncol 2014;132:142-8.
8. National Health Service Cervical Screening Programme. Achievable Standards, Benchmarks for Reporting and Criteria for Evaluating Cervical Cytopathology, 3rd edn. NHS Cancer Screening Programmes, Sheffield: NHSCSP Publication; 2013 No 1.
9. Sargent A, Bailey A, Alimonte MGC et al. Optimal threshold for a positive hybrid capture 2 test for detection of human papillomavirus: data from the ARTISTIC trial. J Clin Microbiol 2010;48:554-8.
10. Meijer CJ, Berkhof J, Castle PE et al. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer 2009;124:516-20.
11. Cuzick J, Cadman L, Mesher D et al. Comparing the performance of six human papillomavirus tests in a screening population. Br J Cancer 2013;108:908-13.
12. Mesher D, Szarewski A, Cadman L et al. Comparison of human papillomavirus testing strategies for triage of women referred with low-grade cytological abnormalities. Eur J Cancer 2013;49:2179-86.
13. Szarewski A, Mesher D, Cadman L et al. Comparison of seven tests for high-grade cervical intraepithelial neoplasia in women with abnormal smears: the Predictors 2 study. J Clin Microbiol 2012;50:1867-73.
14. Carozzi FM, Burroni E, Bisanzi S et al. Comparison of clinical performance of Abbott RealTime High Risk HPV test with that of Hybrid Capture 2 assay in a screening setting. J Clin Microbiol 2011;49:1446-51.
15. Monsonego J, Hudgens MG, Zerat L et al. Evaluation of oncogenic human papillomavirus RNA and DNA tests with liquid-based cytology in primary cervical cancer screening: the FASE study. Int J Cancer 2011;129:691-701.
16. Poljak M, Ostrbenk A. The Abbott RealTime High Risk HPV test is a clinically validated human papillomavirus assay for triage in the referral population and use in primary cervical cancer screening in women 30 years and older: a review of validation studies. Acta Dermatovenerol Alp Panonica Adriat 2013;22:43-7.
17. Heideman DA, Hesselink AT, Berkhof J et al. Clinical validation of the Cobas 4800 HPV test for cervical screening purposes. J Clin Microbiol 2011;49:3983-5.
18. Poljak M, Kocjan BJ. Commercially available assays for multiplex detection of alpha human papillomaviruses. Expert Rev Anti Infect Ther 2010;8:1139-62.
19. Cubie HA, Cuschieri K. Understanding HPV tests and their appropriate applications. Cytopathology 2013;24:289-308.